InTheMoneyStock...'s  Instablog
Send Message
InTheMoneyStocks.Com is a research and consulting company focused on mathematical proprietary techniques along with a key understanding of price, pattern and time. Through understanding geometry and other technical analysis methods, InTheMoneyStocks.Com prides itself on avoiding Wall Street hype... More
My company:
My blog:
Pro Traders Rant and Rave Blog
  • Two Small Bio Stocks Ready To Blast: Labopharm Inc. (NASDAQ:DDSS), Spherix Inc. (NASDAQ:SPEX) 1 comment
    Feb 10, 2010 1:43 PM | about stocks: ENDP, SPEX

    As I look over the destruction in the small cap biotech arena recently, I cannot help but come to the conclusion that these two small cap biotech stocks are undervalued.  Both stocks are way off their highs when great drug news was recently revealed.  Each has pulled back by close to, if not more than 50% from those highs.

    Labopharm Inc. (NASDAQ:DDSS) is the first I wish to highlight. This stock had great news about a week ago when they got FDA approval for their drug OLEPTRO.  This drug is an extended release tablet, once-daily formulation of the antidepressant Trazodone.  This drug may revolutionize the antidepresent drug market.  When the FDA granted Labopharm approval for OLEPTRO, the stock traded close to $3.50 pre market. It opened the day at $2.99 and fell like a rock.  This was a classic, sell the news type event.  Since then, shorts have piled on board and pushed it to a low two days ago of $1.80.  Since then it has rebounded back to just over $2.00.  It is very possible to see this stock trade back over $3.00 in the near term on any deals.  The key is whether or not they will have to dilute the companies shares to raise capital and how they execute the selling of the drug.  I am giving Labopharm a major positive bias at anything under $2.00 with a general trade max to $2.50 - $3.00 short term.

    The other company that looks extremely promising is Spherix Incorporated (NASDAQ:SPEX) a small cap biotech with a promising drug on the horizon.  Naturlose is the drug used to treat type 2 diabetes.  The key revolves around the drug being a natural substance.  Just days ago the company released positive interim results in the phase 3 trial.  The interim trial showed major reductions in variability of HbA1c levels.  As the phase 3 trial winds down, begin to watch this tiny 17 million market cap company inch higher in my opinion.  This drug could be a major player in the future.  Spherix Inc. will most likely search out a partner and that alone could be the driver of a major move back over $2.00.  I am issuing a major positive bias on Spherix Inc. with a possible move over $2.00 in the short term.

    Both these companies show themselves to be on the verge of the big time.  Whether they get bought out, try and make it on their own or partner up, they have the potential to truly become a monster among small fish.

    Gareth Soloway
    Chief Market Strategist

    Stocks: ENDP, SPEX
Back To's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • KtgGroup
    , contributor
    Comments (147) | Send Message
    Blast off like a failed Russian ICBM launch. 10 million share dilution at $2. Ha.
    11 Feb 2010, 11:43 PM Reply Like
Full index of posts »
Latest Followers


  • Utility #stocks leading markets higher despite slightly higher yields in the 10-year U.S. #Treasury. $SO, $ED, $XLU all higher today.
    Apr 20, 2015
  • $YELP Forming Bearish Chart....
    Apr 13, 2015
  • $WMT bearish base, daily 200-day ma. Should drop to the $78.00 level & present a good entry level to buy the stock.
    Apr 10, 2015
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.